288 related articles for article (PubMed ID: 19706150)
21. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
Abbas Z; Yakoob J; Jafri W; Ahmad Z; Azam Z; Usman MW; Shamim S; Islam M
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):630-9. PubMed ID: 24722560
[TBL] [Abstract][Full Text] [Related]
22. Saccharomyces boulardii CNCM I-745 in different clinical conditions.
Dinleyici EC; Kara A; Ozen M; Vandenplas Y
Expert Opin Biol Ther; 2014 Nov; 14(11):1593-609. PubMed ID: 24995675
[TBL] [Abstract][Full Text] [Related]
23. Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline.
Roy Sarkar S; Mitra Mazumder P; Chatterjee K; Sarkar A; Adhikary M; Mukhopadhyay K; Banerjee S
Physiol Behav; 2021 Jul; 236():113411. PubMed ID: 33811908
[TBL] [Abstract][Full Text] [Related]
24. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.
Lee SK; Kim YW; Chi SG; Joo YS; Kim HJ
Dig Dis Sci; 2009 Feb; 54(2):255-63. PubMed ID: 18612822
[TBL] [Abstract][Full Text] [Related]
25.
Lenka S; Singh D; Paul S; Gayen A; Chandra M
ACS Infect Dis; 2021 Apr; 7(4):733-745. PubMed ID: 33703881
[TBL] [Abstract][Full Text] [Related]
26. Influence of
Stier H; Bischoff SC
Clin Exp Gastroenterol; 2016; 9():269-279. PubMed ID: 27695355
[TBL] [Abstract][Full Text] [Related]
27. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review.
Tung JM; Dolovich LR; Lee CH
Can J Gastroenterol; 2009 Dec; 23(12):817-21. PubMed ID: 20011734
[TBL] [Abstract][Full Text] [Related]
28. Yeasts as probiotics: Mechanisms, outcomes, and future potential.
Sen S; Mansell TJ
Fungal Genet Biol; 2020 Apr; 137():103333. PubMed ID: 31923554
[TBL] [Abstract][Full Text] [Related]
29. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients.
Lewis SJ; Potts LF; Barry RE
J Infect; 1998 Mar; 36(2):171-4. PubMed ID: 9570649
[TBL] [Abstract][Full Text] [Related]
30. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study.
Villarruel G; Rubio DM; Lopez F; Cintioni J; Gurevech R; Romero G; Vandenplas Y
Acta Paediatr; 2007 Apr; 96(4):538-41. PubMed ID: 17306006
[TBL] [Abstract][Full Text] [Related]
31. Saccharomyces boulardii does not prevent relapse of Crohn's disease.
Bourreille A; Cadiot G; Le Dreau G; Laharie D; Beaugerie L; Dupas JL; Marteau P; Rampal P; Moyse D; Saleh A; Le Guern ME; Galmiche JP;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):982-7. PubMed ID: 23466709
[TBL] [Abstract][Full Text] [Related]
32. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells.
Dahan S; Dalmasso G; Imbert V; Peyron JF; Rampal P; Czerucka D
Infect Immun; 2003 Feb; 71(2):766-73. PubMed ID: 12540556
[TBL] [Abstract][Full Text] [Related]
33. Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic.
Justino PFC; Franco AX; Pontier-Bres R; Monteiro CES; Barbosa ALR; Souza MHLP; Czerucka D; Soares PMG
Cytokine; 2020 Jan; 125():154791. PubMed ID: 31401369
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Two Forms of Loperamide-Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial.
Cottrell J; Koenig K; Perfekt R; Hofmann R;
Drugs R D; 2015 Dec; 15(4):363-73. PubMed ID: 26541878
[TBL] [Abstract][Full Text] [Related]
35. Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptide.
Liu CH; Chang JH; Chang YC; Mou KY
J Mol Med (Berl); 2020 Dec; 98(12):1675-1687. PubMed ID: 33025105
[TBL] [Abstract][Full Text] [Related]
36. Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans.
Fidan I; Kalkanci A; Yesilyurt E; Yalcin B; Erdal B; Kustimur S; Imir T
Mycoses; 2009 Jan; 52(1):29-34. PubMed ID: 18627477
[TBL] [Abstract][Full Text] [Related]
37. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
38. Interaction of Saccharomyces boulardii with intestinal brush border membranes: key to probiotic effects?
Buts JP; De Keyser N
J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):532-3. PubMed ID: 20706146
[TBL] [Abstract][Full Text] [Related]
39. Saccharomyces boulardii effects on gastrointestinal diseases.
Zanello G; Meurens F; Berri M; Salmon H
Curr Issues Mol Biol; 2009; 11(1):47-58. PubMed ID: 18780946
[TBL] [Abstract][Full Text] [Related]
40. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.
Brun P; Scarpa M; Marchiori C; Sarasin G; Caputi V; Porzionato A; Giron MC; Palù G; Castagliuolo I
PLoS One; 2017; 12(7):e0181863. PubMed ID: 28732069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
